Table 3.

Median change (interquartile range) of circulating biomarkers

			Baseline	Six weeks	Change
Variable	Treat.	N Obs	Median IQR	Median IQR	Median IQR	Contrast1	P
IGF1 ng/mL	P	25	146 (117 to 177)	151 (105 to 205)	-0.5 (-14.5 to 12)	T vs. R	0.87
	R	50	134.5 (113 to 174)	126 (104 to 157)	-10.1 (-30.4 to 13)	T + R vs. P	0.15
	T	50	137.5 (113 to 170)	137 (92.7 to 168)	-13 (-27 to 11)
IGFBP-3 µg/mL	P	25	4.16 (3.75 to 4.76)	4.42 (3.79 to 4.84)	-0.09 (-0.29 to 0.22)	T vs. R	0.05
	R	50	4.22 (3.84 to 4.71)	4.58 (4.07 to 5.11)	0.41 (0 to 0.69)	T + R vs. P	0.22
	T	50	4.28 (3.72 to 4.73)	4.42 (3.87 to 4.78)	0.02 (-0.25 to 0.37)
IGF1/BP3 ratio	P	25	0.18 (0.16 to 0.21)	0.18 (0.15 to 0.24)	0 (-0.03 to 0.02)	T vs. R	0.41
	R	50	0.17 (0.15 to 0.21)	0.16 (0.12 to 0.17)	-0.03 (-0.05 to 0)	T + R vs. P	0.01
	T	50	0.18 (0.15 to 0.2)	0.17 (0.13 to 0.19)	-0.01 (-0.04 to 0)
SHBG nmol/L	P	25	65.9 (39 to 94)	53.5 (36 to 86)	-7.7 (-22 to 3.4)	T vs. R	0.92
	R	50	63.45 (43.3 to 96.4)	78.1 (50.7 to 101)	7.7 (-7.3 to 18.5)	T + R vs. P	0.32
	T	50	64.3 (47.8 to 80.4)	69.6 (51.7 to 86.8)	2.2 (-7.1 to 21.9)
Testosterone	P	25	0.26 (0.17 to 0.34)	0.28 (0.16 to 0.35)	0.02 (-0.08 to 0.07)	T vs. R	0.90
ng/mL	R	50	0.23 (0.16 to 0.32)	0.27 (0.18 to 0.36)	0.03 (-0.03 to 0.09)	T + R vs. P	0.10
	T	50	0.23 (0.19 to 0.32)	0.27 (0.22 to 0.34)	0.02 (-0.02 to 0.09)
Estradiol ng/mL	P	25	120.3 (51.4 to 167.4)	104.35 (45.1 to 179.4)	-9.6 (-99.6 to 91)	T vs. R	0.45
	R	50	94.35 (41.9 to 147.4)	124.7 (65.5 to 209)	27 (-62.9 to 159.08)	T + R vs. P	0.05
	T	50	103.25 (61.98 to 165.5)	160.7 (70.86 to 306.4)	29.5 (-37.3 to 179.8)

IQR, interquartile range; IGF, insulin-like growth factor; P, placebo; R, raloxifene 60 mg/day; T, tamoxifen 10 mg/week; IGFBP-3, insulin-like growth factor-binding protein 3; SHBG, sex hormone-binding globulin.

*Contrast are between tamoxifen arm versus Raloxifene are and either treatment versus placebo.